RHYTHM PHARMACEUTICALS, INC. (RYTM) Current Ratio
- Current ratio · latest quarter: Value 3.45×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.45× | Current assets / current liabilities. $426.56M ÷ $123.59M ≈ 3.45× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 426.56M USD | Assets, Current |
| Current obligations | 123.59M USD | Liabilities, Current |
| Cash and equivalents | 65.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 40.41M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 30.52M USD | Inventory, Net |
| Payables | 16.16M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 12.70M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $426.56M | $123.59M | $65.61M | (m) | $40.41M | $30.52M | $16.16M | $12.70M | 3.45× |
| 2026-03-31 | $430.09M | $103.20M | $62.14M | (m) | $34.19M | $28.65M | $12.30M | $10.13M | 4.17× |
| 2025-12-31 | $466.92M | $105.94M | $54.30M | (m) | $26.08M | $25.75M | $13.95M | $7.30M | 4.41× |
| 2025-09-30 | $494.80M | $104.27M | $52.08M | (m) | $33.03M | $22.11M | $13.63M | $5.56M | 4.75× |
| 2025-06-30 | $360.68M | $129.46M | $135.59M | (m) | $26.12M | $18.87M | $15.98M | $3.78M | 2.79× |
| 2025-03-31 | $369.29M | $111.82M | $106.09M | (m) | $17.82M | $19.32M | $11.91M | $1.59M | 3.30× |
| 2024-12-31 | $374.20M | $115.52M | $89.14M | (m) | $18.51M | $18.74M | $12.33M | $1.54M | 3.24× |
| 2024-09-30 | $340.34M | $97.61M | $47.52M | (m) | $19.31M | $13.89M | $4.89M | (m) | 3.49× |
| 2024-06-30 | $357.37M | $54.72M | $161.67M | (m) | $17.60M | $11.99M | $4.54M | (m) | 6.53× |
| 2024-03-31 | $235.75M | $54.16M | $53.43M | (m) | $14.70M | $8.51M | $7.55M | (m) | 4.35× |
| 2023-12-31 | $308.27M | $55.20M | $60.08M | (m) | $14.87M | $8.62M | $4.88M | (m) | 5.58× |
| 2023-09-30 | $329.20M | $50.14M | $64.59M | (m) | $14.54M | $7.76M | $3.84M | (m) | 6.57× |
| 2023-06-30 | $283.88M | $46.10M | $115.68M | (m) | $13.83M | $6.18M | $8.38M | (m) | 6.16× |
| 2023-03-31 | $317.84M | $46.03M | $109.66M | (m) | $8.12M | $5.49M | $13.35M | (m) | 6.91× |
| 2022-12-31 | $354.24M | $39.81M | $127.68M | (m) | $6.22M | $2.92M | $4.80M | (m) | 8.90× |
| 2022-09-30 | $361.87M | $33.10M | $185.09M | (m) | $3.33M | (m) | $4.93M | (m) | 10.93× |
| 2022-06-30 | $249.33M | $44.57M | $113.21M | (m) | $1.71M | (m) | $6.01M | (m) | 5.59× |
| 2022-03-31 | $253.45M | $47.27M | $78.54M | (m) | $862.00K | (m) | $12.01M | (m) | 5.36× |
| 2021-12-31 | $308.39M | $43.43M | $59.25M | (m) | $1.02M | $111.00K | $5.74M | (m) | 7.10× |
| 2021-09-30 | $335.64M | $23.47M | $92.37M | (m) | (m) | (m) | $4.61M | (m) | 14.30× |
| 2021-06-30 | $378.45M | $17.46M | $69.34M | (m) | (m) | (m) | $5.01M | (m) | 21.68× |
| 2021-03-31 | $412.13M | $16.85M | $87.27M | (m) | (m) | (m) | $9.15M | (m) | 24.46× |
| 2020-12-31 | $181.67M | $17.99M | $100.85M | (m) | (m) | (m) | $4.90M | (m) | 10.10× |
| 2020-09-30 | $209.91M | $15.85M | $67.67M | (m) | (m) | (m) | $3.79M | (m) | 13.25× |
| 2020-06-30 | $237.82M | $14.90M | $59.09M | (m) | (m) | (m) | $4.76M | (m) | 15.96× |
| 2020-03-31 | $267.86M | $17.70M | $55.78M | (m) | (m) | (m) | $5.93M | (m) | 15.14× |
| 2019-12-31 | $302.40M | $24.42M | $62.29M | (m) | (m) | (m) | $10.41M | (m) | 12.38× |
| 2019-09-30 | $170.88M | $25.21M | $71.68M | (m) | (m) | (m) | $7.75M | (m) | 6.78× |
| 2019-06-30 | $203.50M | $26.09M | $63.12M | (m) | (m) | (m) | $6.57M | (m) | 7.80× |
| 2019-03-31 | $230.17M | $12.57M | $42.02M | (m) | (m) | (m) | $3.99M | (m) | 18.32× |
| 2018-12-31 | $258.69M | $13.58M | $49.54M | (m) | (m) | (m) | $7.64M | (m) | 19.05× |
| 2018-09-30 | $276.54M | $7.80M | $58.25M | (m) | (m) | (m) | $208.00K | (m) | 35.44× |
| 2018-06-30 | $290.77M | $7.25M | $210.48M | (m) | (m) | (m) | $3.31M | (m) | 40.12× |
| 2018-03-31 | $138.41M | $5.58M | $43.17M | (m) | (m) | (m) | $2.46M | (m) | 24.81× |
| 2017-12-31 | $150.67M | $6.72M | $34.24M | (m) | (m) | (m) | $2.43M | (m) | 22.42× |
| 2017-09-30 | $32.04M | $5.46M | $27.91M | $2.50M | (m) | (m) | $2.27M | (m) | 5.87× |
| 2016-12-31 | $11.18M | $4.73M | $6.54M | $4.00M | (m) | (m) | $1.90M | (m) | 2.36× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |